Pharmacology, Toxicology and Pharmaceutical Science
Omega-3 Fatty Acid
100%
End Stage Renal Disease
82%
Hemodialysis
59%
Placebo
51%
Ciclosporin
38%
Pharmacokinetics
35%
Cardiovascular Disease
34%
Tacrolimus
29%
Intervention Trial
23%
Docosahexaenoic Acid
23%
Phospholipid
23%
Calcineurin Inhibitor
20%
Lipoprotein
19%
HIV
17%
Brain Natriuretic Peptide
17%
Adiponectin
17%
Human Immunodeficiency Virus Infection
17%
N(g),n(g) Dimethylarginine
17%
6 N,n' Dimethylarginine
17%
Fatty Acid
17%
Diabetes Mellitus
17%
Atrial Fibrillation
17%
Homocysteine
17%
Intervention Study
17%
Polyunsaturated Fatty Acid
8%
Chronic Disease
8%
Trough Level
8%
Prospective Study
8%
Triacylglycerol
7%
Sudden Cardiac Death
7%
Elimination
5%
Bioavailability
5%
Heart Infarction
5%
Volume of Distribution
5%
Icosapentaenoic Acid
5%
Immunology and Microbiology
Blood Plasma
58%
Kidney Transplantation
53%
Hemodialysis
40%
Adiponectin
35%
Kidney Function
30%
Ciclosporin
26%
Insulin Sensitivity
19%
Human Immunodeficiency Virus Infection
17%
Amino Terminal Sequence
17%
Transplant Procedure
17%
Insulin Release
17%
Tacrolimus
17%
Phospholipid Blood Level
17%
Pharmacokinetics
17%
Neutrophil
17%
Human Immunodeficiency Virus
17%
Lipocalin
17%
QT Interval
17%
Blood Level
11%
Lipid Blood Level
10%
Triacylglycerol Blood Level
10%
Glucose Metabolism
8%
Allotransplantation
7%
Body Mass
7%
Normal Human
5%
Medicine and Dentistry
Kidney Transplantation
53%
Kidney Graft
41%
Biopsy
35%
Kidney Function
23%
Diabetes Mellitus
21%
Insulin Sensitivity
19%
Insulin Release
17%
Calcineurin Inhibitor
17%
Graft Survival
17%
Neutrophil Gelatinase Associated Lipocalin
17%
Cohort Study
17%
Adiponectin
17%
Interstitium
17%
Cyclosporine
11%
Diabetes
11%
Tacrolimus
11%
Kidney Allograft
11%
Body Mass Index
9%
Prospective Study
8%
Glomerulus
7%
Reproducibility
7%
Stereology
6%
Transplantation
5%
Glucose Metabolism
5%
Biological Marker
5%
Kidney Injury
5%
Glucose Tolerance
5%